Combination chemotherapy in the treatment of adenocarcinoma of unknown primary origin.
A total of 21 patients with histologic diagnosis of metastatic adenocarcinoma and an occult primary tumor were treated with combination chemotherapy. The regimen consisted of cyclophosphamide, vincristine, methotrexate, and 5-fluorouracil (COMF). The overall response rate was 47.6%. Six patients (28.6%) achieved complete response (mean duration, 36.5 months) and four patients (19%) achieved partial response (mean duration, 7.7 months). Toxicity was manageable and occurred in 14 patients (67%). The COMF combination serves as a broad-spectrum chemotherapy regimen in adenocarcinoma of unknown primary origin.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate